By Stephen Nakrosis

Sanofi and Regeneron Pharmaceuticals Inc. said Wednesday the Food and Drug Administration approved Dupixent to treat patients with prurigo nodularis.

Dupixent, or dupilumab, is the first and only medicine specifically indicated to treat prurigo nodularis, a skin disease that can cause painful lesions, in the U.S. The companies said there are about 75,000 adults in the U.S. living with prurigo nodularis.

According to the companies, "Dupixent significantly reduced itch and skin lesions compared to placebo in direct-to-Phase 3 program consisting of two pivotal trials."

Dupixent has also been given regulatory approvals in one or more countries to treat certain patients with atopic dermatitis, asthma and various other ailments. More than 500,000 patients have been treated with Dupixent globally, according to the companies.

Write to Stephen Nakrosis at stephen.nakrosis@wsj.com

(END) Dow Jones Newswires

September 28, 2022 18:50 ET (22:50 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.
Grafico Azioni Sanofi (EU:SAN)
Storico
Da Giu 2024 a Lug 2024 Clicca qui per i Grafici di Sanofi
Grafico Azioni Sanofi (EU:SAN)
Storico
Da Lug 2023 a Lug 2024 Clicca qui per i Grafici di Sanofi